Artificial Intelligence Enhanced ECG To Detect Cardiac Amyloidosis

Overview

About this study

This pragmatic trial will be the first study to prospectively evaluate the use of the AI ECG dashboard along with an augmented report in everyday practice. The findings will also guide future implementation strategies and inform the translation of many of the current and future AI algorithms into the clinical setting. The participants are the providers/clinicians. Basic demographic information about the providers will be collected as well as their reactions to the trial based educational guidance supplied to them. Patient health information will be collected on their patients using a HIPPA waiver. There will be no patient contact. We will reveiew 29,000 ekgs.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Eligible providersinclude cardiology or hematology providers (physicians andadvanced practiceproviders) who

care for adult patients, and

consent to participate on this study

Patient data will becollected for those patients who have an ECGobtainedduring the period ofthe studyprovidingthe patient

has a clinic appointmentwith the consented provider

is≥30 years of agehas not denied access to medical records

is no talready included in the database due to a previous encounter with a consented provider

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Jacksonville, Fla. Mayo Clinic principal investigator Melissa Lyle, M.D.	Closed-enrolling by invitation What is this? (?) "Close" Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.	Contact information: Ann Engebretson 5072931965 engebretson.ann@mayo.edu
Rochester, Minn. Mayo Clinic principal investigator Angela Dispenzieri, M.D.	Closed-enrolling by invitation What is this? (?) "Close" Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.	Contact information: Ann Engebretson 5072931965 engebretson.ann@mayo.edu
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Rafael Fonseca, M.D.	Closed-enrolling by invitation What is this? (?) "Close" Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.	Contact information: Ann Engebretson 5072931965 engebretson.ann@mayo.edu
Eau Claire, Wis. Mayo Clinic principal investigator Michel Barsoum, M.B., Ch.B.	Closed-enrolling by invitation What is this? (?) "Close" Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.	Contact information: Ann Engebretson 5072931965 engebretson.ann@mayo.edu

Mayo Clinic Location

Status

Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Melissa Lyle, M.D.

Closed-enrolling by invitation

Contact information:

Ann Engebretson

5072931965

engebretson.ann@mayo.edu

Rochester, Minn.

Mayo Clinic principal investigator

Angela Dispenzieri, M.D.

Closed-enrolling by invitation

Contact information:

Ann Engebretson

5072931965

engebretson.ann@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Rafael Fonseca, M.D.

Closed-enrolling by invitation

Contact information:

Ann Engebretson

5072931965

engebretson.ann@mayo.edu

Eau Claire, Wis.

Mayo Clinic principal investigator

Michel Barsoum, M.B., Ch.B.

Closed-enrolling by invitation

Contact information:

Ann Engebretson

5072931965

engebretson.ann@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials